Table 2.

Frequency, site, and type of malignancies in our PsA cohort taking traditional DMARD therapy.

No. Patients Taking Various DMARDNo. Patients Showing Malignancies (%)Site and Type of Malignancies (no. patients)
159; MTX15 (4.6)Squamous cell skin carcinoma (2); breast cancer (2); meningioma (2); colon-rectum carcinoma (1); kidney carcinoma (1); ovarian cancer (1); prostate cancer (1); non-Hodgkin lymphoma (1); uterine cancer (1); squamous cell carcinoma of the tongue (1); seminoma (1); papillary thyroid carcinoma (1)
80; SSZ5 (1.5)Bladder cancer (2); breast carcinoma (2); uterine cancer (1)
25; CSA1 (0.3)Squamous cell skin carcinoma (1)
21; LEF3 (0.9)Carcinoid (2); meningioma (1)
4; AZA1 (0.3)Breast cancer (1)
15; MTX plus SSZ3 (0.9)Melanoma (2); colon-rectum carcinoma (1)
9; MTX plus AZA2 (0.6)Melanoma (2)
5; MTX plus CSA1 (0.3)Seminoma (1)
4; MTX plus LEF1 (0.3)Breast cancer (1)
  • PsA: psoriatic arthritis; DMARD: disease-modifying antirheumatic drug; MTX: methotrexate; SSZ: sulfasalazine; CSA: cyclosporine; LEF: leflunomide; AZA: azathioprine.